GENERATING CK19-POSITIVE CELLS WITH HAIR-LIKE STRUCTURES FROM WHARTONS JELLY
    4.
    发明申请
    GENERATING CK19-POSITIVE CELLS WITH HAIR-LIKE STRUCTURES FROM WHARTONS JELLY 有权
    生成CK19-阳性细胞,其中含有类似结构的JELLY

    公开(公告)号:US20140148915A1

    公开(公告)日:2014-05-29

    申请号:US13874054

    申请日:2013-04-30

    IPC分类号: A61L27/36

    摘要: A method of differentiating cells into CK19-positive cells capable of producing hair follicle-like and hair structure-like can include: providing a tissue scaffold; seeding cells into the scaffold, the cells being capable of differentiation; incubating the scaffold having the cells in a cell growth media; and incubating the scaffold having the cells in an osteogenic differentiation medium sufficient for CK19-positive cells to be generated in the scaffold. The tissue scaffold can be a decellularized Whartons' jelly matrix. The cell growth media excludes osteogenic differentiation components: dexamethasone, β-glycerophosphate, 1α,25-hydroxyvitamin D3, and ascorbic acid 2-phosphate. The osteogenic differentiation medium includes the osteogenic differentiation components. The cells can be mesenchymal cells, such as WJMSCs.

    摘要翻译: 将细胞分化成能够产生毛囊样和毛发结构的CK19阳性细胞的方法可以包括:提供组织支架; 将细胞接种到支架中,细胞能够分化; 将具有细胞的支架在细胞生长培养基中孵育; 并将具有细胞的支架在成骨分化培养基中孵育,足以使CK19阳性细胞在支架中产生。 组织支架可以是脱细胞的沃顿饮料基质。 细胞生长培养基排除成骨分化成分:地塞米松,甘油磷酸酯,1α,25-羟基维生素D3和2-磷酸抗坏血酸。 成骨分化培养基包括成骨分化成分。 细胞可以是间充质细胞,如WJMSCs。

    REPROGRAMMING OF HUMAN WHARTON'S JELLY CELLS TO PRODUCE HAIR CELLS
    8.
    发明申请
    REPROGRAMMING OF HUMAN WHARTON'S JELLY CELLS TO PRODUCE HAIR CELLS 审中-公开
    人类JELLY细胞生成细胞毛发的重现

    公开(公告)号:US20170067018A1

    公开(公告)日:2017-03-09

    申请号:US15353244

    申请日:2016-11-16

    IPC分类号: C12N5/0793 C12N15/113

    摘要: A method of transforming human cells into mechanosensory hair cells (MHCs), such as inner hear hair cells in the cochlea and vestibular organs, can include: causing human Wharton's jelly cells (hWJCs) to increase expression of or biological function of HATH1 so as to transform the hWJCs into MHCs. The method can include; administering a nucleic acid that encodes HATH1 to the hWJCs; causing inhibited expression of or biological function of HES1 and/or HES5 in the hWJCs; administering a nucleic acid that inhibits HES1 and/or a nucleic acid that inhibits HES5 to the hWJCs; causing inhibited expression of or biological function of HES1 and/or HES5 in the WJCs by administering a nucleic acid that inhibits HES1 and/or a nucleic acid that inhibits HES5; nucleic acids are administered includes a sequence of SEQ ID NO: 2, SEQ ID NO: 3, and/or SEQ ID NO: 4.

    摘要翻译: 将人类细胞转化为机械感染毛细胞(MHC)的方法,例如耳蜗和前庭器官内部听到的毛细胞,可以包括:引起人类沃顿的果冻细胞(hWJCs)增加HATH1的表达或生物学功能,以便 将hWJCs转化为MHC。 该方法可以包括 向hWJCs施用编码HATH1的核酸; 导致hWJCs中HES1和/或HES5的表达或生物学功能受到抑制; 施用抑制HES1的核酸和/或对hWJC抑制HES5的核酸; 通过施用抑制HES1的核酸和/或抑制HES5的核酸来抑制WJCs中HES1和/或HES5的表达或生物学功能; 核酸被给予包括SEQ ID NO:2,SEQ ID NO:3和/或SEQ ID NO:4的序列。

    HYDROGEL PRECURSORS HAVING NANOPARTICLES
    9.
    发明申请
    HYDROGEL PRECURSORS HAVING NANOPARTICLES 审中-公开
    具有纳米颗粒的HYDROGEL PRECURSORS

    公开(公告)号:US20160038643A1

    公开(公告)日:2016-02-11

    申请号:US14918229

    申请日:2015-10-20

    摘要: An implantable hydrogel precursor composition can include: a cross-linkable polymer matrix that is biocompatible; and a plurality of polymer particles in the cross-linkable polymer matrix. The cross-linkable polymer matrix can include a cross-linkable hyaluronic acid polymer that has cross-linkable functional groups. The hyaluronic acid polymer can be a methacrylated hyaluronic acid polymer. The methacrylated hyaluronic acid polymer can have a molecular weight from about 500 kDa to about 1.8 MDa. The polymer particles can include a cross-linked hyaluronic acid. The cross-linkable polymer matrix having the polymer particles has a yield stress. The cross-linkable polymer matrix having the polymer particles has shape retention at physiological temperatures. The composition can include live cells in the cross-linkable polymer matrix. The composition can include a biologically active agent in the cross-linkable polymer matrix.

    摘要翻译: 可植入水凝胶前体组合物可以包括:可生物相容的可交联聚合物基质; 和可交联聚合物基质中的多个聚合物颗粒。 可交联聚合物基质可以包括具有可交联官能团的可交联的透明质酸聚合物。 透明质酸聚合物可以是甲基丙烯酸酯化的透明质酸聚合物。 甲基丙烯酸酯化的透明质酸聚合物可以具有约500kDa至约1.8MDa的分子量。 聚合物颗粒可以包括交联的透明质酸。 具有聚合物颗粒的可交联聚合物基质具有屈服应力。 具有聚合物颗粒的可交联聚合物基质在生理温度下具有形状保持性。 组合物可以包括可交联聚合物基质中的活细胞。 组合物可以在可交联的聚合物基质中包括生物活性剂。

    Methacrylated devitalized cartilage and devitalized cartilage particles

    公开(公告)号:US10744228B2

    公开(公告)日:2020-08-18

    申请号:US15254709

    申请日:2016-09-01

    摘要: An implantable composition can include methacrylated solubilized devitalized cartilage (MeSDVC) with or without devitalized cartilage (DVC) particles. These compositions can be hydrogel precursors. After implantation, the MeSDVC may be crosslinked so as to form a hydrogel. The crosslinked hydrogel can include the DVC particles. A hydrogel precursor matrix (e.g., not crosslinked) can include a crosslinkable substance that can be crosslinked into a hydrogel, where DVC particles are included in the precursor matrix. The hydrogel precursor matrix can be located in a tissue defect site, such as a hole or recess in a cartilage or bone, and then crosslinked into a hydrogel that has the DVC particles therein.